Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.3969 -0.0025 (-0.63%)
Official Closing Price Updated: 6:30 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 4 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo. 
Via Benzinga
Who's Who In Cannabis: Latest Executive Changes You Should Know About
 
Via Benzinga
IGC Raises $3M Via Private Placement With Asset Management Firm Bradbury
IGC Pharma, Inc. (AMEX: IGC) bagged a strategic investment  
Via Benzinga
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
--News Direct-- 
Via News Direct
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
 
Via Benzinga
EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
IGC Pharma's breakthrough Alzheimer's drug, IGC-AD1, shows promising interim results in reducing cognitive and behavioral symptoms, offering hope for patients and families. Its dual-action capability... 
Via Benzinga
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed. 
Via Benzinga
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss... 
Via Benzinga
IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1
--News Direct-- 
Via News Direct
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses
IGC Pharma's Q3 2024 results: Navigating financial dips with strategic patents in pain treatment and Alzheimer's therapy. 
Via Benzinga
Topics Intellectual Property
Why IGC Pharma Stock Is Moving Higher
IGC Pharma highlighted data from a trial in which the group treated with TGR-63 showed a 78% and 85% reduction in the cortical and hippocampal amyloid load, respectively, reaffirming its potential to... 
Via Benzinga
AI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment Research
IGC Pharma partners with University of Los Andes, to leverage AI for improving Alzheimer's disease treatment and clinical trial efficiency. 
Via Benzinga
Topics Artificial Intelligence
Cannabis Based Pain Relief Solution Receives European Patent Approval
IGC Pharma, Inc. (NYSE American: IGC) has been granted European Patent No. 3193862 by the European Patent Office for its innovative "Cannabinoid Composition and Method for Treating Pain." 
Via Benzinga
Topics Cannabis Intellectual Property
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
IGC Pharma FY23 Revenue Grows 129%, What About Net Loss?
IGC Pharma, Inc. (AMEX:IGC) released its financial results for the fiscal year ended March 31, 2023, revealing revenue of $911,000, an increase of 129% compared to $397,000 in fiscal year 2022. FY 2023... 
Via Benzinga
IGC Pharma Secures $12M Credit Facility From O-Bank To Aid Alzheimer's Research
IGC Pharma, Inc. (AMEX: IGC) has recently secured a $12 million credit from the  
Via Benzinga
IGC Pharma Secures $3M Via Private Placement
IGC Pharma, Inc. (AMEX:IGC) announced a strategic investment from four investment funds managed by Bradbury Asset Management (Hong Kong) Limited, an asset management firm with over $2 billion in... 
Via Benzinga
Why VBI Vaccines Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket
Gainers Akumin Inc. (NASDAQ: AKU) shares surged 58.2% to $0.2865 in pre-market trading. Akumin recently named Krishna Kumar as President and Chief Operating Officer of the Company. 
Via Benzinga
12 Industrials Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
IGC Announces Rebranding, Changes Name To IGC Pharma
India Globalization Capital, Inc. (AMEX:IGC) announced it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better... 
Via Benzinga
IGC Q3 2023 Revenue Grows 133% YoY, What About Net Loss?
India Globalization Capital, Inc. (dba IGC, Inc.) (AMEX:IGC) released its third fiscal quarter 2023 financial results, revealing revenue of $332,000, a 133% increase compared to $142,000 in the Q3... 
Via Benzinga
IGC Expanding Clinical Trials Of THC Based Drug Following Approval From Health Canada
India Globalization Capital, Inc. (AMEX:IGC) has received a no objection letter from Health Canada for approval of its trial, “A phase 2, multi-center, double-blind, randomized, placebo-controlled... 
Via Benzinga
IGC Starts Phase 2 Clinical Trials Of THC Based Drug Candidate For The Treatment Of Agitation In Dementia From Alzheimer's Disease
India Globalization Capital, Inc. (AMEX:IGC) has begun “A phase 2, multi-center, double-blind, randomized, placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants... 
Via Benzinga
IGC Q2 2023 Revenue Grows 261%, THC Based Drug For Alzheimer's Entering Phase 2 Trials
India Globalization Capital, Inc. (AMEX:IGC) reported its second fiscal quarter 2023 financial results, revealing revenue of $202,000, a 261% increase compared to $56,000 in the same quarter of 2022. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.